Neurodevelopmental disability · preterm infants
It is very uncertain whether higher changes neurodevelopmental disability compared with lower amino acid intake (very low certainty).
1 finding from 1 review
Postnatal growth failure (weight < 10th percentile) · preterm infants
It is very uncertain whether higher changes postnatal growth failure at discharge (weight < 10th centile) compared with lower amino acid intake (very low certainty).
1 finding from 1 review
Weight gain · preterm infants
1 finding from 1 review
Head circumference gain (mm/week) · preterm infants
1 finding from 1 review
Retinopathy of prematurity · preterm infants
It is very uncertain whether higher changes retinopathy of prematurity compared with lower amino acid intake (very low certainty).
1 finding from 1 review
Abnormal blood urea nitrogen (various criteria) · preterm infants
Higher leads to higher abnormal blood urea nitrogen (various criteria) compared with lower amino acid intake (high certainty).
1 finding from 1 review
Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review
Weight gain · formula‐fed low birth weight infants
1 finding from 1 review
Linear growth (cm/week) · formula‐fed low birth weight infants
1 finding from 1 review
Growth: head circumference (cm/week) · formula‐fed low birth weight infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IQ score and Bayley score at 18 months or later · formula‐fed low birth weight infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Necrotising enterocolitis · formula‐fed low birth weight infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HDL‐cholesterol · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: No clinically important improvement ‐ global evaluation ‐ when compared with standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) showed no clear difference in mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
3 findings from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
4 findings from 1 review
Show 1 more finding